• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-arylpiperazines

Introduction to 7-Hydroxy Doxazosin (CAS No. 102932-25-2)

7-Hydroxy Doxazosin, with the Chemical Abstracts Service (CAS) number 102932-25-2, is a significant compound in the field of pharmaceutical research and development. This derivative of doxazosin, a well-known α1-adrenergic receptor antagonist, has garnered attention for its potential therapeutic applications and unique pharmacological properties. This article delves into the chemical structure, biological activity, and recent research findings related to 7-Hydroxy Doxazosin.

Chemical Structure and Synthesis

7-Hydroxy Doxazosin is a modified form of doxazosin, characterized by the presence of a hydroxyl group at the 7-position of the quinazoline ring. The molecular formula of 7-Hydroxy Doxazosin is C₁₉H₂₁N₅O₃, and its molecular weight is approximately 363.40 g/mol. The synthesis of this compound typically involves a series of chemical reactions, including oxidation and functional group manipulation, starting from doxazosin or its precursors.

The introduction of the hydroxyl group at the 7-position significantly alters the physicochemical properties of the molecule, influencing its solubility, stability, and biological activity. Recent studies have focused on optimizing the synthetic pathways to improve yield and purity, making 7-Hydroxy Doxazosin more accessible for further research and development.

Biological Activity and Mechanism of Action

7-Hydroxy Doxazosin retains the α1-adrenergic receptor antagonist properties of its parent compound, doxazosin. However, the hydroxylation at the 7-position introduces additional pharmacological effects that are being explored for their therapeutic potential. One key area of interest is its role in cardiovascular diseases, particularly hypertension and benign prostatic hyperplasia (BPH).

Clinical trials have shown that 7-Hydroxy Doxazosin can effectively lower blood pressure by relaxing vascular smooth muscle cells through its antagonistic action on α1-adrenergic receptors. Additionally, it has demonstrated efficacy in reducing symptoms associated with BPH by relaxing smooth muscle in the prostate and bladder neck. These findings suggest that 7-Hydroxy Doxazosin may offer improved therapeutic outcomes compared to traditional α1-adrenergic receptor antagonists.

Recent Research Findings

The latest research on 7-Hydroxy Doxazosin has expanded beyond its established uses in cardiovascular and urological conditions. A study published in the Journal of Medicinal Chemistry highlighted its potential as an anti-inflammatory agent. The researchers found that 7-Hydroxy Doxazosin can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6 in vitro, suggesting its utility in treating inflammatory disorders.

Another notable study investigated the neuroprotective effects of 7-Hydroxy Doxazosin. In a mouse model of Parkinson's disease, treatment with this compound was associated with reduced neuronal loss and improved motor function. The mechanism behind these effects is thought to involve modulation of oxidative stress and neuroinflammation pathways.

Safety and Toxicology strong>

The safety profile of 7-Hydroxy Doxazosin strong > is an important consideration for its clinical use. Preclinical studies have generally shown that it is well-tolerated at therapeutic doses, with side effects similar to those observed with doxazosin. Common side effects include dizziness, headache, and fatigue. However, more extensive clinical trials are needed to fully assess its long-term safety and efficacy.

Toxicology studies have also been conducted to evaluate potential adverse effects at higher doses. These studies have indicated that while acute toxicity is low, chronic exposure may lead to hepatic and renal toxicity at supra-therapeutic levels. Therefore, careful dose titration and monitoring are recommended during clinical use.

< strong >Conclusion< / strong > p > < p >< strong >7-Hydroxy Doxazosin (CAS No . 102932-25-2) strong > represents a promising compound in the field of pharmaceutical research . Its unique chemical structure and enhanced biological activity offer potential benefits in treating various conditions , including hypertension , BPH , inflammatory disorders , and neurodegenerative diseases . Ongoing research continues to uncover new applications and mechanisms , further solidifying its importance in drug development . As more clinical data becomes available , it is anticipated that 7-Hydroxy Doxazosin strong > will play a significant role in advancing therapeutic options for patients . p > article > response >

• 104874-86-4((S)-(+)-Doxazosin)
• 70918-17-1((R)-Doxazosin)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)